By proceeding, you agree to our Terms of Use and Privacy Policy.
Revolutionizing Genetic Therapy Development & Delivery to the Eye The Race Is On; Luxturna Remains the Only Approved Gene Therapy for the Eye, Who Will Be the Next? The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting is bringing you even more world class content, bringing you two tracks of learning to tackle the pressing challenges faced i
he event will mainly focus on challenges faced with drug targets including wet AMD, dry AMD, DME, IRDs and more.
Join 40+ speakers from the industry leaders in ophthalmic gene therapy such as: Adverum, REGENXBIO, Novartis, Janssen, Kriya etc
You will discover novel vector engineering, disease models, clinical trials design, patient enrolment platforms and more.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Best in class in vitro models to accurately predict in vivo outcomes.
Biomere is a global, nonclinical contract research organization (CRO) with locations on the east and west coast, as well as multiple locations in China (JOINN).
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality.
Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.